{"hands_on_practices": [{"introduction": "The skin's outermost layer, the stratum corneum, maintains an acidic pH known as the 'acid mantle,' which is critical for barrier function and antimicrobial defense. In atopic dermatitis, genetic mutations in filaggrin can impair this function. This practice problem models how a deficiency in filaggrin breakdown products, such as urocanic acid, directly impacts skin pH, providing a quantitative link between a genetic defect and a key biophysical property of the skin [@problem_id:4766720].", "problem": "A patient with atopic dermatitis has a loss-of-function mutation in the filaggrin gene, reducing the formation of Natural Moisturizing Factor (NMF), including urocanic acid. In the stratum corneum, urocanic acid contributes to the acid mantle by supplying acid equivalents to the aqueous phase associated with the corneocytes. Assume the following are true for a local, well-mixed patch of stratum corneum water:\n\n- The buffering capacity, defined as the magnitude of strong acid or base required per unit change in $\\,\\mathrm{pH}\\,$ per liter, is constant over the small range of interest and is $\\beta = 10$ $\\mathrm{mmol}$ per $\\mathrm{pH}$-unit per liter.\n- The initial acid content attributable to filaggrin breakdown products is $5$ $\\mathrm{mmol}$ per liter of stratum corneum water.\n- A $50\\%$ decrease in filaggrin breakdown to urocanic acid reduces the acid content proportionally (i.e., the acid equivalents attributable to urocanic acid fall by $50\\%$), and other acid-base contributors remain unchanged.\n\nStarting from the definition of buffering capacity and the concept of small perturbations in acid equivalents, derive the expected change in $\\,\\mathrm{pH}\\,$ due to the loss of $50\\%$ of urocanic acid equivalents. State the direction of change based on acid removal. Report your final answer as a pure number (unitless). Do not round; give the exact value.", "solution": "The problem asks for the change in $\\mathrm{pH}$ in a local patch of stratum corneum water due to a genetically induced reduction in acid production from filaggrin. The solution can be derived from the definition of buffering capacity provided.\n\nFirst, the problem must be validated.\n**Step 1: Extract Givens**\n- Buffering capacity, $\\beta$, is constant and equals $10$ $\\mathrm{mmol}$ per $\\mathrm{pH}$-unit per liter. In mathematical terms, $\\beta = 10 \\, \\frac{\\mathrm{mmol}}{\\mathrm{L} \\cdot \\mathrm{pH}}$.\n- The initial acid content attributable to filaggrin breakdown products is $C_{A, \\text{initial}} = 5 \\, \\frac{\\mathrm{mmol}}{\\mathrm{L}}$.\n- A loss of $50\\%$ of urocanic acid equivalents occurs. This is stated to reduce the acid content proportionally. This is interpreted to mean that the acid content from this source, $C_{A, \\text{initial}}$, is reduced by $50\\%$.\n- Other acid-base contributors are assumed to remain unchanged.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded in the pathophysiology of atopic dermatitis, where filaggrin mutations lead to a compromised acid mantle. The concepts of buffering capacity and acid-base chemistry are fundamental scientific principles. The problem is well-posed, providing a clear definition of buffering capacity and the necessary quantitative data to solve for the change in $\\mathrm{pH}$. The language is objective and the values, while part of a simplified model, are not scientifically implausible. The problem is therefore deemed valid and a solution can be derived.\n\n**Derivation of the Solution**\nThe buffering capacity, $\\beta$, is defined as the magnitude of strong acid or base required to change the $\\mathrm{pH}$ by one unit in one liter of solution. For a change in acid concentration, $\\Delta C_A$, causing a change in $\\mathrm{pH}$, $\\Delta \\mathrm{pH}$, the relationship for small perturbations is:\n$$ \\beta = -\\frac{\\Delta C_A}{\\Delta \\mathrm{pH}} $$\nThe negative sign indicates that the addition of acid ($\\Delta C_A > 0$) causes a decrease in $\\mathrm{pH}$ ($\\Delta \\mathrm{pH} < 0$), ensuring that $\\beta$ is a positive quantity.\n\nWe are given the initial concentration of acid equivalents derived from filaggrin:\n$$ C_{A, \\text{initial}} = 5 \\, \\frac{\\mathrm{mmol}}{\\mathrm{L}} $$\nThe problem states there is a loss of $50\\%$. The change in acid concentration, $\\Delta C_A$, is therefore a reduction of $50\\%$ of the initial amount.\n$$ \\Delta C_A = -0.50 \\times C_{A, \\text{initial}} $$\n$$ \\Delta C_A = -0.50 \\times 5 \\, \\frac{\\mathrm{mmol}}{\\mathrm{L}} = -2.5 \\, \\frac{\\mathrm{mmol}}{\\mathrm{L}} $$\nThe negative sign signifies a loss of acid from the system.\n\nWe are also given the buffering capacity:\n$$ \\beta = 10 \\, \\frac{\\mathrm{mmol}}{\\mathrm{L} \\cdot \\mathrm{pH}} $$\nWe can now solve for the change in $\\mathrm{pH}$, $\\Delta \\mathrm{pH}$, by rearranging the definition of buffering capacity:\n$$ \\Delta \\mathrm{pH} = -\\frac{\\Delta C_A}{\\beta} $$\nSubstituting the calculated value for $\\Delta C_A$ and the given value for $\\beta$:\n$$ \\Delta \\mathrm{pH} = -\\frac{-2.5 \\, \\frac{\\mathrm{mmol}}{\\mathrm{L}}}{10 \\, \\frac{\\mathrm{mmol}}{\\mathrm{L} \\cdot \\mathrm{pH}}} $$\nThe units of $\\frac{\\mathrm{mmol}}{\\mathrm{L}}$ cancel out, leaving the result in units of $\\mathrm{pH}$.\n$$ \\Delta \\mathrm{pH} = \\frac{2.5}{10} $$\n$$ \\Delta \\mathrm{pH} = 0.25 $$\nThe direction of the change is determined by the sign of $\\Delta \\mathrm{pH}$. Since $\\Delta \\mathrm{pH}$ is positive, this represents an increase in $\\mathrm{pH}$. This is chemically consistent: a loss of acid makes the solution less acidic (more alkaline), corresponding to a higher $\\mathrm{pH}$ value. The problem asks for the expected change in $\\mathrm{pH}$ as a pure number.", "answer": "$$\\boxed{0.25}$$", "id": "4766720"}, {"introduction": "Beyond clinical appearance, atopic dermatitis and psoriasis are defined by distinct underlying immune pathways. We can now use molecular data, such as gene expression in a skin lesion, to classify the 'endotype' of the inflammation. This exercise will guide you through calculating a T2:T17 signature ratio from hypothetical transcriptomic data, demonstrating how we can quantitatively distinguish between the T-helper 2-driven inflammation of atopic dermatitis and the T-helper 17-driven inflammation of psoriasis [@problem_id:4766781].", "problem": "A clinical transcriptomic analysis of lesional skin from a patient with chronic inflammatory dermatitis quantifies messenger ribonucleic acid (mRNA) fold-changes relative to matched non-lesional skin for canonical axis-defining cytokines. The T-helper type 2 (T2) axis is represented by interleukin-13 (IL13), interleukin-31 (IL31), and thymic stromal lymphopoietin (TSLP). The T-helper 17 (T17) axis is represented by interleukin-17A (IL17A) and interleukin-23A (IL23A). The observed fold-changes are: IL13, IL31, and TSLP each up by $20$-fold; IL17A and IL23A each up by $1.5$-fold.\n\nStarting from the following foundational facts:\n- In immunopathology of atopic dermatitis and psoriasis, axis intensity is inferred from expression of signature cytokines: the T2 axis (IL13, IL31, TSLP) is characteristically elevated in atopic dermatitis, whereas the IL-17/IL-23 T17 axis is characteristically elevated in psoriasis.\n- Fold-change measurements are multiplicative, and aggregation that respects multiplicative scaling is achieved by linear operations in the natural logarithm domain. Mapping back to the original scale yields a geometric mean as the appropriate central tendency for fold-change-based signatures.\n\nUse these bases to derive a principled aggregation for each axis and compute a T2:T17 signature ratio $R$ as the aggregated T2 signature divided by the aggregated T17 signature. Then, classify the endotype using a threshold $T=5$ by defining a classification code $C$ where $C=1$ if $R \\geq T$ (T2-dominant endotype, consistent with atopic dermatitis-like) and $C=0$ if $R < T$ (T17-dominant endotype, consistent with psoriasis-like).\n\nExpress $R$ as a dimensionless number rounded to four significant figures. Provide your final answer as a row matrix containing $R$ and $C$ in that order.", "solution": "The problem statement has been rigorously validated and is determined to be valid. It is scientifically grounded in immunopathology, well-posed with all necessary data and definitions provided, and objective in its formulation. The problem constitutes a formal and solvable quantitative analysis of transcriptomic data.\n\nThe task is to compute a T2:T17 signature ratio, denoted as $R$, and a classification code, $C$, based on fold-change data from a patient's skin biopsy. The methodology for aggregating cytokine expression data within an axis is explicitly defined as the geometric mean, which is appropriate for multiplicative measures such as fold-changes.\n\nFirst, we identify the given fold-change values for each cytokine axis.\nFor the T-helper type 2 (T2) axis, the signature cytokines are IL13, IL31, and TSLP. The number of cytokines in this axis is $n_{T2} = 3$. The observed fold-changes are provided as:\n$f_{IL13} = 20$\n$f_{IL31} = 20$\n$f_{TSLP} = 20$\n\nFor the T-helper 17 (T17) axis, the signature cytokines are IL17A and IL23A. The number of cytokines in this axis is $n_{T17} = 2$. The observed fold-changes are:\n$f_{IL17A} = 1.5$\n$f_{IL23A} = 1.5$\n\nThe problem states that the aggregation of fold-changes for a given axis is performed by calculating their geometric mean. The geometric mean (GM) of a set of $n$ values $\\{x_1, x_2, \\dots, x_n\\}$ is given by the formula:\n$$ \\text{GM} = \\left(\\prod_{i=1}^{n} x_i\\right)^{1/n} $$\nAs noted in the problem statement, this is equivalent to performing a linear average on the natural logarithms of the values and then transforming back to the original scale:\n$$ \\text{GM} = \\exp\\left(\\frac{1}{n} \\sum_{i=1}^{n} \\ln(x_i)\\right) $$\n\nWe compute the aggregated T2 signature, $S_{T2}$, by taking the geometric mean of the T2 axis fold-changes:\n$$ S_{T2} = (f_{IL13} \\times f_{IL31} \\times f_{TSLP})^{1/n_{T2}} $$\nSubstituting the given values:\n$$ S_{T2} = (20 \\times 20 \\times 20)^{1/3} = (20^3)^{1/3} = 20 $$\n\nNext, we compute the aggregated T17 signature, $S_{T17}$, by taking the geometric mean of the T17 axis fold-changes:\n$$ S_{T17} = (f_{IL17A} \\times f_{IL23A})^{1/n_{T17}} $$\nSubstituting the given values:\n$$ S_{T17} = (1.5 \\times 1.5)^{1/2} = ((1.5)^2)^{1/2} = 1.5 $$\n\nThe T2:T17 signature ratio, $R$, is defined as the aggregated T2 signature divided by the aggregated T17 signature:\n$$ R = \\frac{S_{T2}}{S_{T17}} $$\nUsing the calculated values for $S_{T2}$ and $S_{T17}$:\n$$ R = \\frac{20}{1.5} = \\frac{40}{3} \\approx 13.3333... $$\nThe problem requires that $R$ be rounded to four significant figures.\n$$ R = 13.33 $$\n\nFinally, we classify the endotype using the classification code $C$. The rule is defined with a threshold $T=5$:\n$C=1$ if $R \\geq T$\n$C=0$ if $R < T$\n\nWe compare our calculated value of $R$ to the threshold $T=5$:\n$$ 13.33 \\geq 5 $$\nThis inequality is true. Therefore, the classification code is:\n$$ C = 1 $$\nThis result indicates a T2-dominant endotype, consistent with an atopic dermatitis-like immunopathology.\n\nThe final answer requires a row matrix containing $R$ and $C$ in that order.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n13.33 & 1\n\\end{pmatrix}\n}\n$$", "id": "4766781"}, {"introduction": "Understanding the molecular basis of disease allows for the development of highly specific therapies. Following our discussion of the T2 immune axis in atopic dermatitis, this problem explores the mechanism of dupilumab, a monoclonal antibody that targets this pathway. You will apply the principles of receptor-ligand binding to calculate the receptor occupancy at a typical drug concentration, illustrating the powerful efficacy of modern biologic treatments in blocking pathogenic signaling [@problem_id:4766760].", "problem": "Interleukin-4 receptor alpha ($IL-4R\\alpha$) mediates signaling by interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key drivers of Type 2 helper T cell (Th2) inflammation in atopic dermatitis. Dupilumab is a human monoclonal antibody that binds $IL-4R\\alpha$ and functionally blocks IL-4 and IL-13 signaling. Consider the following scenario: at steady-state trough in serum, the total dupilumab concentration is $50\\,\\mu\\mathrm{g}/\\mathrm{mL}$. The equilibrium dissociation constant for the dupilumab:$IL-4R\\alpha$ interaction is $K_d=0.1\\,\\mu\\mathrm{g}/\\mathrm{mL}$. Assume reversible $1:1$ binding, ligand (dupilumab) present in large excess such that the free ligand concentration equals its total serum concentration, equilibrium is reached, and competition from endogenous cytokines at the binding epitope is negligible.\n\nStarting from the law of mass action and the fundamental definition of the equilibrium dissociation constant for a reversible $1:1$ receptor–ligand interaction, derive an expression for the fraction of receptors occupied by ligand in terms of the free ligand concentration and $K_d$. Then, use it to calculate the receptor occupancy of $IL-4R\\alpha$ by dupilumab at the given trough concentration. Finally, infer qualitatively whether IL-4/IL-13 signaling would be substantially inhibited in atopic dermatitis at this occupancy, noting that psoriasis is primarily driven by the interleukin-23/interleukin-17 axis.\n\nExpress the receptor occupancy as a unitless decimal fraction. Round your final numerical answer to four significant figures.", "solution": "The pathophysiologic link between cytokine receptor engagement and downstream signaling can be quantified at equilibrium using the law of mass action for a reversible $1:1$ interaction between receptor and ligand. Let $[R]$ denote the concentration of free receptor, $[L]$ the concentration of free ligand, and $[RL]$ the concentration of the receptor–ligand complex. The equilibrium dissociation constant is defined as\n$$\nK_d \\equiv \\frac{[R][L]}{[RL]}.\n$$\nThe fraction of receptors occupied by ligand, denoted $\\theta$, is defined as\n$$\n\\theta \\equiv \\frac{[RL]}{[R]_{\\text{tot}}},\n$$\nwhere $[R]_{\\text{tot}}$ is the total receptor concentration, and by conservation $[R]_{\\text{tot}} = [R] + [RL]$. This implies $[RL] = \\theta [R]_{\\text{tot}}$ and $[R] = (1-\\theta)[R]_{\\text{tot}}$.\n\nSubstituting these into the definition of $K_d$ gives\n$$\nK_d = \\frac{[R][L]}{[RL]} = \\frac{(1-\\theta)[R]_{\\text{tot}}\\, [L]}{\\theta [R]_{\\text{tot}}} = \\frac{(1-\\theta)[L]}{\\theta}.\n$$\nSolving this equation for $\\theta$ in terms of $[L]$ and $K_d$ yields\n$$\n\\theta = \\frac{[L]}{[L] + K_d}.\n$$\nUnder the stated assumptions, the free ligand concentration equals the measured serum trough concentration of dupilumab, so we take $[L] = 50\\,\\mu\\mathrm{g}/\\mathrm{mL}$ and $K_d = 0.1\\,\\mu\\mathrm{g}/\\mathrm{mL}$. Substituting,\n$$\n\\theta = \\frac{50}{50 + 0.1} = \\frac{50}{50.1}.\n$$\nCompute the value:\n$$\n\\theta = 0.9980039920318725\\ldots\n$$\nRounding to four significant figures, as requested, gives\n$$\n\\theta = 0.9980.\n$$\n\nInterpretation for signaling: With $\\theta \\approx 0.9980$, nearly all $IL-4R\\alpha$ molecules are occupied by dupilumab. Assuming occupancy directly correlates with functional blockade of ligand-induced receptor activation for this competitive antagonist, IL-4/IL-13 signaling in atopic dermatitis would be expected to be substantially inhibited at trough. In psoriasis, where the dominant pathophysiology involves the interleukin-23/interleukin-17 axis rather than IL-4/IL-13, such $IL-4R\\alpha$ blockade would be expected to have minimal direct impact on the core inflammatory signaling.", "answer": "$$\\boxed{0.9980}$$", "id": "4766760"}]}